Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis

Asgharzadeh, Fereshteh; Hashemzehi, Milad; Moradi‐Marjaneh, Reyhaneh; Hassanian, Seyed Mahdi; Ferns, Gordon A.; Khazaei, Majid; Avan, Amir

doi:10.1016/j.lfs.2019.117181

Cited by 22 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a large nationwide Finnish cohort, the authors found a significant reduction in mortality due to breast cancer in RASB users, also featuring a dose-effect, suggesting a mechanistic association [ 84 ]. Similarly, concurring elements supported that urological cancer survival improved with RASB use [ 85 , 86 , 87 , 88 , 89 ]. In non-small-cell lung cancer, RASB use with platinum and taxol chemotherapy was associated with improved survival [ 90 , 91 ].…”

Section: Part 1: Renin–angiotensin System Blockers and Malignanciesmentioning

confidence: 82%

Renin–Angiotensin–Aldosterone System and Immunomodulation: A State-of-the-Art Review

Laghlam

Jozwiak

Nguyen

2021

Cells

View full text Add to dashboard Cite

The renin–angiotensin system (RAS) has long been described in the field of cardiovascular physiology as the main player in blood pressure homeostasis. However, other effects have since been described, and include proliferation, fibrosis, and inflammation. To illustrate the immunomodulatory properties of the RAS, we chose three distinct fields in which RAS may play a critical role and be the subject of specific treatments. In oncology, RAS hyperactivation has been associated with tumor migration, survival, cell proliferation, and angiogenesis; preliminary data showed promise of the benefit of RAS blockers in patients treated for certain types of cancer. In intensive care medicine, vasoplegic shock has been associated with severe macro- and microcirculatory imbalance. A relative insufficiency in angiotensin II (AngII) was associated to lethal outcomes and synthetic AngII has been suggested as a specific treatment in these cases. Finally, in solid organ transplantation, both AngI and AngII have been associated with increased rejection events, with a regional specificity in the RAS activity. These elements emphasize the complexity of the direct and indirect interactions of RAS with immunomodulatory pathways and warrant further research in the field.

show abstract

Section: Part 1: Renin–angiotensin System Blockers and Malignanciesmentioning

confidence: 82%

Renin–Angiotensin–Aldosterone System and Immunomodulation: A State-of-the-Art Review

Laghlam

Jozwiak

Nguyen

2021

Cells

View full text Add to dashboard Cite

show abstract

“…Consistent with these findings, ARBs and ACEIs have been reported to reduce tumor growth and vascularization in a wide range of cancers, suggesting a role for Ang II in cancer development and progression [ 4 ]. We summarized the studies containing ARBs in the last ten years and revealed the effects on OS and DSS across different malignancies ( Table 7 ) [ 5 – 8 , 18 – 23 ]. However, there was no consistent conclusion on whether ARBs have a survival benefit in patients coexisting with malignancies.…”

Section: Discussionmentioning

confidence: 99%

Angiotensin II receptor blockers and oral squamous cell carcinoma survival: A propensity-score-matched cohort study

Chen

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

Objectives Angiotensin II receptor blockers (ARBs) improve the survival rates of patients with various cancers. However, it remains unclear whether ARBs confer a survival benefit on patients with oral squamous cell carcinoma (OSCC). Here, we assessed the associations between ARB use and survival in patients with OSCC of different stages. Materials and methods This was a 10-year retrospective cohort study of OSCC patients. We enrolled 7,558 patients diagnosed with oral cancer between January 2007 and December 2017 whose details had been entered into the Chang Gung Research Database. Seven hundred and fourteen patients were recruited from the Chang Gung Research Database after performing 1:1 propensity score-matching between ARB users and non-users. Cox’s regression models with adjusted covariates were employed to detect factors influencing the survival rates of patients with OSCC. Results Kaplan-Meier analysis revealed that the overall survival (OS) rate of 180-day ARB users increased (p = 0.038). Cox’s regression models indicated that ARB use, younger patients, early-stage OSCC, and patients without diabetes mellitus were independently prognostic of improved OS. Increased OS was more prominent in 180-day ARB users in stage III, Iva, and IVb categories. Conclusions ARB use for more than 180 days is associated with an increased survival rate and is a positive, independent prognostic factor in patients with OSCC. A further two-arm study should be conducted to confirm the clinical usefulness of ARBs in OSCC patients.

show abstract

“…The same agents retain a role in cancer and neurodegenerative conditions suggesting that targeting common (in this case OxS-related) pathways may represent a successful pharmacological strategy for the prevention of multiple diseases, although always keeping in mind that the OxS damage does not represent the only event in the pathogenesis of these conditions [1,47].…”

Section: Cardiovascular Disease Drugs With Antioxidant Properties As An Example For Shared Disease Pathways and Common Pharmacological Prmentioning

confidence: 99%

Targeting Oxidative Stress for Disease Prevention and Therapy: Where Do We Stand, and Where Do We Go from Here

2020

View full text Add to dashboard Cite

Oxidative stress (OxS) is one of the main processes related to aging and a common denominator of many different chronic/degenerative diseases (e.g., cardiovascular and neurodegenerative conditions and cancer). Thus, its potential modulation by supplementation/pharmacological therapy caused a lot of interest. However, these expectations have been mitigated by the obtainment of controversial results (beneficial, null, or adverse effects) following antioxidant interventions. Here, we discuss the current understanding of OxS assessment in health and disease, challenges and the potential of its evaluation in clinical practice, and available and future development for supplementation and pharmacologic strategies targeting OxS.

show abstract

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers as therapeutic options in the treatment of renal cancer: A meta-analysis

Cited by 22 publications

References 17 publications

Renin–Angiotensin–Aldosterone System and Immunomodulation: A State-of-the-Art Review

Renin–Angiotensin–Aldosterone System and Immunomodulation: A State-of-the-Art Review

Angiotensin II receptor blockers and oral squamous cell carcinoma survival: A propensity-score-matched cohort study

Targeting Oxidative Stress for Disease Prevention and Therapy: Where Do We Stand, and Where Do We Go from Here

Contact Info

Product

Resources

About